Cancer Vaccine Articles & Analysis
52 news found
This formulation can be used to develop mRNA cancer vaccines without modification of any active targeting ligand. Compared to LNPs formulated with ALC-0315, a key component of the U.S. ...
This critical information holds immense potential in unraveling immune responses, gaining insights into autoimmune diseases, advancing cancer immunotherapy, and propelling vaccine development. CD Genomics' latest enhancements in TCR-Seq technology promise to provide even more accurate and comprehensive insights into the adaptive immune system. ...
Vaccines protect against a range of diseases, including measles, polio, diphtheria, tetanus, meningitis, influenza and cancer. ...
ByNuvonis
Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. ...
ByArdigen
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. ...
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a ...
Agnieszka Blum, MD, PhD will continue her mission as the General Director of the Immunology Business Unit at Ardigen, where she focuses on developing AI platforms to solve therapy development problems in cell therapies, cancer vaccines, and TCR-mimicking antibodies. Agnieszka Blum, MD, PhD has served as the General Director of Immunology since October 2020. ...
ByArdigen
Jubilant Therapeutics Inc. is developing a novel small molecule PAD4 inhibitor that directly targets this mechanism. The findings appear in Cancer Research, a journal of the American Association for Cancer Research. “Development of metastases remains a leading cause of death from cancer. Tumor-associated neutrophils have long been ...
ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ...
About VBI-1901 and GBM VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. ...
The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. The VACCS just completed year three of the planned five year trial. ...
ByCalviri
Median overall survival and 18-month overall survival data continue to show improvements over historical controls1 One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline Next steps : Recurrent GBM: randomized, controlled evaluation with potential to support accelerated approval application expected to initiate in Q3 2022 ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society ...
Belichard will provide an overview of the progress the Company has made with its advanced OncoMimics™ pipeline, including its first-in-class off-the-shelf therapeutic cancer vaccine, EO2401, as well as its other fully owned EndoMimics™ pipeline for immune diseases using its Mimicry drug discovery platform. ...
ByEnterome
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy at the American Society of Clinical Oncology (ASCO) ...
ByEnterome
” Details of the poster presentation are as follows: Poster Board Number: W-215 Session Title: Cancer – Immunotherapy, Cancer Vaccines III Location: Hall D, Walter E. ...
(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical trial of VAC2, an allogeneic cancer vaccine product candidate, for the treatment of non-small cell lung ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present additional positive immunogenicity and clinical data on TG4050, its individualized neoantigen cancer vaccine. TG4050 is currently being evaluated in two ongoing multicenter Phase I trials in patients ...
About Scancell Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications, development of a vaccine for COVID-19 and a growing portfolio of novel anti-TaG monoclonal antibodies. ImmunoBody® ...
ByScancell
Riva will work with Transgene’s CEO Hedi Ben Brahim to realize the potential of the Company’s technology platforms and products to benefit cancer patients. Transgene’s Board of Directors also proposes the appointment of Prof. ...